For example, an ERBB2-amplified intestinal tumor-like organoid exhibited significant responsiveness to the dual ERBB2/EGFR inhibitor lapatinib, but not to a strain with an epidermal growth factor receptor-amplified status with a normal ERBB2 allele (59). Here, EGFR is linked to intestinal neoplasm.